Pramlintide
As of the edition of 20 October 2026, Pramlintide is a protein: marketed, first approved in 2005 (US); acts on CALCR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Protein
- Brand name
- Symlin
- First approved
- 16 March 2005 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- AstraZeneca
- Registered trials
- 36, 5 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Immune system; Mental health; Bones, joints and muscles; Cancer
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Pramlintide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCR | Calcitonin receptor | P30988 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 5 | 0 | 1 |
| Phase 1 | 4 | 2 | 1 | 1 |
| Phase 2 | 10 | 9 | 0 | 1 |
| Phase 3 | 6 | 3 | 0 | 1 |
| Phase 4 | 8 | 7 | 0 | 1 |
| All trials | 36 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Acquired holder and Lead sponsor of trials | 2002 to now |